Expression of matrix metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) in medullary thyroid carcinoma: Prognostic implications

Thyroid

Volumn 18, Issue 8, 2008, Pages 865-871

  Cavalheiro, Beatriz G ^a   Junqueira, Consuelo Rodrigues ^b   Brandão, Lenine G ^b  

^a Brazilian Institute for Cancer Control IBCC   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; THYROID MEDULLARY CARCINOMA; THYROID SURGERY;

ADOLESCENT; ADULT; AGED; CARCINOMA, MEDULLARY; CHILD; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; PROGNOSIS; THYROID NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 50649112589     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0412     Document Type: Article

References (43)

1. Yoon SO, Park SJ, Yun CH, Chung AS 2003 Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 36:128-137.
2. Kraiem Z, Korem S 2000 Matrix metalloproteinases and the thyroid. Thyroid 10:1061-1069.
3. Raza SL, Cornelius LA 2000 Matrix metalloproteinases: pro-and anti-angiogenic activities. J Investig Dermatol Symp Proc 5:47-54.
4. Bhattacharyya N 2003 A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma. Otolaryngol Head Neck Surg 128:115-123.
5. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA 1984 Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 63:319-342.
6. Tavares MR 2003 Distribution of neck lymph nodes metastases in medullary thyroid carcinoma [thesis]. São Paulo: São Paulo University Medical School. Available from: http://dedalus.usp.br:4500/ALEPH/POR/USP/USP/TES/FULL/ 1332733?
7. Gilliland FD, Hunt WC, Morris DM, Key CR 1997 Prognostic factors for thyroid carcinoma. A population-based study of 15698 cases from surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer 79:564-573.
8. Ezabella MCL 1998 Medullary thyroid carcinoma: analysis of 62 cases in their clinical and evolutive aspects, and in diagnosis and conduct in tumor recurrence [thesis]. São Paulo: São Paulo University Medical School. Available from: http://dedalus.usp.br:4500/ALEPH/POR/USP/USP/TES/FULL/0983923?
9. Kebebew E, Ituarte PHG, Siperstein AE, Quan-Yang D, Clark OH 2000 Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and comparison of staging systems. Cancer 88:1139-1148.
10. Hyer SL, Vini L, A'Hern R, Harmer C 2000 Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 26:686-690.
11. Kaserer K, Scheuba C, Neuhold N, Weinhäusel A, Haas O, Vierhapper H, Nierdele B 2001 Sporadic versus familial medullary thyroid microcarcinoma: a histopathologic study of 50 consecutive patients. Am J Surg Pathol 25:1245-1251.
12. Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli JP, Schlumberger M 2003 Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging. Br J Cancer 88:1537-1542.
13. Kameyama K, Takami H 2004 Medullary thyroid carcinoma: nationwide Japanese survey of 634 cases in 1996 and 271 cases in 2002. Endocr J 51:453-456.
14. Brauckhoff M, Gimm O, Weiss CL, Ukkat J, Sekulla C, Brauckhoff K, Phuong NT, Dralle H 2004 Multiple endocrine neoplasia 2B syndrome due to codon 918 mutation: clinical manifestation and course in early and late onset disease. World J Surg 28:1305-1311.
15. Ellenhorn JDI, Shah JP, Brennan M 1993 Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. Surgery 114:1078-1081.
16. Gimm O, Ukkat J, Dralle H 1998 Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 22:562-568.
17. Scopsi L, Sampietro G, Boracchi P, Del Bo R, Gullo M, Placucci M, Pilotti S 1996 Multivariate analysis of prognostic factors in sporadic medullary carcinoma of the thyroid. A retrospective study of 109 consecutive patients. Cancer 78:2173-2183.
18. Franc B, Rosenberg-Bourgin M, Caillou B, Dutrieux-Berger N, Floquet J, Houcke-Lecomte M, Justrabo E, Lange F, Labat-Moleur F, Le Bodic MF, Patey M, Beauchet A, Saint-André JP, Hejblum G, Viennet G 1998 Medullary thyroid carcinoma: search for histological predictors of survival (109 proband cases analysis). Hum Pathol 29:1078-1084.
19. Guyetant S, Dupre F, Bigorgne JC, Franc B, Dutrieux-Berger N, Lecomte-Houcke M, Patey M, Caillou B, Viennet G, Guerin O, Saint-Andre JP 1999 Medullary thyroid microcarcinoma: a clinicopathologic retrospective study of 38 patients with no prior familial disease. Hum Pathol 30:957-963.
20. Niccoli-Sire P, Murat A, Rohmer V, Gibelin H, Chabrier G, Conte-Devolx B, Visset J, Ronceray J, Jaeck D, Henry JF, Proye C, Carnaille B, Kraimps JL; Groupe D'etude Des Tumeurs Endocrines 2003 When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutation? Surgery 134:1029-1036.
21. Murray GI 2001 Matrix metalloproteinases: a multifunctional group of molecules. J Pathol 195:135-137.
22. Komorowski J, Pasieka Z, Jankiewicz-Wika, Stepien H 2002 Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 12:655-662.
23. a edition. Artmed Editora, Porto Alegre, pp 93-103.
24. Machens A, Ukkat J, Brauckhoff M, Gimm O, Dralle H 2005 Advances in the management of hereditary medullary thyroid cancer. J Intern Med 257:50-59.
25. Hsu SM, Raine L, Fanger H 1981 Use of avidin-biotin-peroxiodase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:283-286.
26. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, Schlumberger M, Bigorgne JC, Dumontier P, Leclerc L, Bernard C, Guilhem I (the GETC Study Group) 1998 Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. Clin Endocrinol (Oxf) 48:265-273.
27. Maeta H, Ohgi S, Terada T 2001 Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas. Virchows Arch 438:121-128.
28. Lin SY, Wang YY, Sheu WHH 2003 Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated to stage progression in papillary thyroid cancer. Clin Endocrinol (Oxf) 58:513-518.
29. Nakamura H, Ueno H, Yamashita K, Shimada T, Yamamoto E, Noguchi M, Fujimoto N, Sato H, Seiki M, Okada Y 1999 Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. Cancer Res 59:467-473.
30. Zedenius J, Ståhle-Bäckdahl M, Enberg U, Grimelius L, Larsson C, Wallin G, Bäckdahl M 1996 Stromal fibroblasts adjacent to invasive thyroid tumors: expression of gelatinase A but not stromalysin 3 mRNA. World J Surg 20:101-106.
31. Cvejić D, Savin S, Paunovic I, Tatic S, Havelka M 2000 Immunohistochemical localization of matrixmetalloproteinase-2 (MMP-2) in medullary thyroid carcinoma. Arch Oncol 8:95-97.
32. Tomita T 1997 Matrix metalloproteinases and tissue inhibitors of metalloproteinases in thyroid C-cells and medullary thyroid carcinomas. Histopathology 31:150-156.
33. Campo E, Merino MJ, Liotta L, Neumann R, Stetler-Stevenson W 1992 Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Hum Pathol 23:1395-1401.
34. Kameyama K 1996 Expression of MMP-1 in the capsule of thyroid cancer-relationship with invasiveness. Path Res Pract 192:20-26.
35. Korem S, Resnick MB, Kraiem Z 1999 Similar and divergent patterns in the regulation of matrix metalloproteinase-1 (MMP-1) and tissue inhibitor of MMP-1 gene expression in benign and malignant human thyroid cells. J Clin Endocrinol Metab 84:3322-3327.
36. Friguglietti CUM, Mello ES, Castro IV, Silva Filho GB, Alves VAF 2000 Metalloproteinase-9 immunoexpression and angiogenesis in thyroid follicular neoplasms: relation to clinical and histopathologic features. Head Neck 22:373-379.
37. Dahlman T, Lammerts E, Wik M, Bergström D, Grimelius L, Westermark K, Rubin K, Heldin NE 2000 Fibrosis in undifferentiated (anaplastic) thyroid carcinomas: evidence for a dual action of tumor cells in collagen type I synthesis. J Pathol 191:376-386.
38. Korem S, Kraiem Z, Shiloni E, Yehezkel O, Sadeh O, Resnick MB 2002 Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma. Isr Med Assoc J 4:247-251.
39. Hofmann A, Laue S, Rost AK, Scherbaum WA, Aust G 1998 mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines. Thyroid 8:203-214.
40. Patel A, Straight AM, Mann H, Duffy E, Fenton C, Dinauer C, Tuttle RM, Francis GL 2002 Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents. J Endocrinol Invest 25:403-408.
41. Baldini E, Toller M, Graziano FM, Russo FP, Pepe M, Biordi L, Marchioni E, Curcio F, Ulisse S, Ambesi-Impiombato FS, D'Armiento M 2004 Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines. Thyroid 14:881-888.
42. Zucker S, Jian C, Wen-Tien C 2000 Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19:6642-6650.
43. Seiki M 2003 Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett 194:1-11.